Breaking News

Adimab, Merck in Tech Transfer Pact

To transfer antibody technology for the discovery and optimization of monoclonal and bispecific therapeutic candidates

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Adimab, LLC has entered into a definitive agreement with Merck to transfer its antibody technology to Merck Research Labs for the discovery and optimization of monoclonal and bispecific therapeutic antibody candidates. This technology transfer expands an ongoing collaboration initiated in 2009 that has resulted in several undisclosed therapeutic candidates for Merck.   Adimab will transfer and license its antibody discovery and optimization platform to Merck. Merck will receive a custom human ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters